Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Merkel Cell × lutetium Lu 177 dotatate × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 15 Paraganglioma 5 Meningioma 5 Pheochromocytoma 4 Carcinoma, Neuroendocrine 4 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma, Medullary 2 Carcinoid Tumor 2 Somatostatinoma 1 Serotonin Syndrome 1 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Parathyroid Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Medulloblastoma 1 Hypertension 1 Disease Progression 1 Carcinoma, Merkel Cell 1 Carcinoid Heart Disease 1 Advanced Lung Neuroendocrine Tumor 1 Adrenal Gland Neoplasms 1 Adenoma, Islet Cell 1

Interventions

pembrolizumab 9 avelumab 9 Nivolumab 7 atezolizumab 4 durvalumab 3 Specimen Handling 3 Biopsy 3 ALT-803 3 talimogene laherparepvec 2 fludarabine phosphate 2 fludarabine 2 domatinostat 2 cemiplimab 2 Radiotherapy 2 Radiosurgery 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 Cyclophosphamide 2 relatlimab 1 oblimersen 1 lutetium Lu 177 dotatate 1 lenvatinib 1 lanreotide 1 cabozantinib 1 aldesleukin 1 advexin 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Opdualag 1 Lidocaine, Prilocaine Drug Combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583708 2025-05-23

iPRRT

Weill Medical College of Cornell University

Phase 2 Recruiting

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡